Trusted Resource for Clinical Trials, Protocols & Progress
Southeast Asia comprises ten nations—Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam. Together, they represent a population of over 650 million and offer:
Click to read the full article.
The ASEAN region includes Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore, Thailand, and Vietnam. While each member state retains its own regulatory authority, ASEAN has initiated several efforts to harmonize standards across member countries to streamline cross-border research activities.
Click to read the full article.
The PMDA collaborates closely with Japan’s Ministry of Health, Labour and Welfare (MHLW) to regulate drug development. Through rigorous scientific evaluations, clinical trial oversight, and post-marketing surveillance, the PMDA supports public health while promoting innovation. Japan’s regulatory framework emphasizes quality assurance, early stakeholder engagement, and global harmonization with ICH guidelines.
Click to read the full article.
ICH Q guidelines cover the quality aspect of pharmaceuticals. These include topics like development, risk management, quality systems, and process validation. While primarily considered during manufacturing phases, their integration into clinical development significantly enhances consistency and regulatory confidence.
Click to read the full article.
The ICH was officially founded in 1990 by regulatory authorities and industry associations from Europe (EMA), the United States (FDA), and Japan (PMDA). Its primary goal was to eliminate redundant clinical trials and create a unified system for developing and approving pharmaceuticals globally.
Click to read the full article.
The ICH was established in 1990 as a tripartite initiative between the EU, US, and Japan. It has since expanded to include regulatory bodies and pharmaceutical industry stakeholders from around the world. The core mission is to achieve greater regulatory harmonization to ensure safe, effective, and high-quality medicines.
Click to read the full article.
Data integrity refers to the completeness, consistency, and accuracy of clinical trial data throughout its lifecycle. ICH E6 mandates that data must be:
Click to read the full article.
ICH E5—Ethnic Factors in the Acceptability of Foreign Clinical Data—helps determine whether clinical data generated in one region is acceptable for use in another. This guideline acknowledges that ethnic differences can influence pharmacokinetics, pharmacodynamics, and clinical outcomes.
Click to read the full article.
ICH E5, titled “Ethnic Factors in the Acceptability of Foreign Clinical Data,” was one of the earlier efforts to recognize how demographic and cultural differences might impact the safety, efficacy, or dosage of a drug across populations. The guideline provides a framework to determine if clinical data from one region can be extrapolated to another through a concept called a bridging study.
Click to read the full article.
ICH M4 defines the framework for organizing information into five key modules. Among these, Modules 2 to 5 are harmonized across ICH regions, while Module 1 is region-specific.
Click to read the full article.
